KNSA logo

Kiniksa Pharmaceuticals International plc (KNSA)

$51.89

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on KNSA

Market cap

$3.99B

EPS

0.91

P/E ratio

59.7

Price to sales

5.49

Dividend yield

--

Beta

0.118927

Price on KNSA

Previous close

$51.58

Today's open

$51.66

Day's range

$51.36 - $52.48

52 week range

$26.27 - $59.87

Profile about KNSA

CEO

Sanj K. Patel

Employees

315

Headquarters

London,

Exchange

Nasdaq Global Select

Shares outstanding

76938016

Issue type

Common Stock

KNSA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on KNSA

Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Jun 10, 2026

news preview

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in June:

news source

GlobeNewsWire • May 29, 2026

news preview

Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation

Kiniksa Pharmaceuticals continues to outperform, with Arcalyst net sales poised to surpass my previous bullish estimates. Arcalyst captured 18% of the recurrent pericarditis market by end-2025, with average therapy duration rising to three years and further upside from a new consumer awareness campaign. KPL-387, a next-generation IL-1 antibody, is set for phase 2 proof-of-concept data in H2 2026, offering improved economics and patient convenience compared to Arcalyst.

news source

Seeking Alpha • Apr 29, 2026

news preview

Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

Its Arcalyst has been on the market for years, yet it posted strong sales growth in the period. More is to come, apparently, as management raised its net sales guidance for the drug.

news source

The Motley Fool • Apr 28, 2026

news preview

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

news source

Seeking Alpha • Apr 28, 2026

news preview

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end – – Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today –

news source

GlobeNewsWire • Apr 28, 2026

news preview

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.

news source

Zacks Investment Research • Apr 28, 2026

news preview

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution.

news source

GlobeNewsWire • Apr 23, 2026

news preview

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

news source

Benzinga • Apr 21, 2026

news preview

What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge

The chief accounting officer of Kiniksa Pharmaceuticals sold 6,625 shares for roughly $309,000 on April 9, 2026. The director reported still holding 27,418 Class A ordinary shares after the transaction.

news source

The Motley Fool • Apr 17, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Kiniksa Pharmaceuticals International plc

Open an M1 investment account to buy and sell Kiniksa Pharmaceuticals International plc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in KNSA on M1